$INTI
Inhibitor Therapeutics, Inc.

2019 Q3 Form 10-Q Financial Statement

#000119312519219046 Filed on August 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $318.5K $331.9K $360.0K
YoY Change -20.4% -7.81% 28.57%
% of Gross Profit
Research & Development $364.4K $303.6K $528.9K
YoY Change -53.0% -42.6% 19.99%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $682.9K $635.5K $884.4K
YoY Change -41.91% -28.14% 22.93%
Operating Profit -$682.9K -$635.5K -$884.4K
YoY Change -41.91% -28.14% 22.93%
Interest Expense $4.370K $2.810K $0.00
YoY Change 9.25%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$678.6K -$632.7K -$880.0K
YoY Change -42.08% -28.1% 22.22%
Income Tax
% Of Pretax Income
Net Earnings -$678.5K -$632.7K -$881.9K
YoY Change -42.08% -28.26% 23.1%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.832K -$1.708K $0.00
COMMON SHARES
Basic Shares Outstanding 370.4M 370.4M 369.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.372M $2.025M $800.0K
YoY Change -4.76% 153.15% -51.22%
Cash & Equivalents $1.372M $2.025M $795.8K
Short-Term Investments
Other Short-Term Assets $50.66K $38.01K $290.0K
YoY Change -1.52% -86.89% 0.0%
Inventory
Prepaid Expenses $50.66K $38.01K $41.06K
Receivables
Other Receivables
Total Short-Term Assets $1.423M $2.063M $1.087M
YoY Change -18.33% 89.84% -43.82%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $61.02K $68.35K $97.64K
YoY Change -32.43% -30.0% -23.08%
Total Long-Term Assets $61.02K $68.35K $97.64K
YoY Change -32.43% -30.0% -23.08%
TOTAL ASSETS
Total Short-Term Assets $1.423M $2.063M $1.087M
Total Long-Term Assets $61.02K $68.35K $97.64K
Total Assets $1.484M $2.132M $1.184M
YoY Change -19.03% 79.96% -42.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $286.0K $195.3K $326.2K
YoY Change -12.81% -40.11% 1.21%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $358.9K $304.8K $461.9K
YoY Change -34.63% -34.02% 36.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M
YoY Change
Total Long-Term Liabilities $3.000M $3.000M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $358.9K $304.8K $461.9K
Total Long-Term Liabilities $3.000M $3.000M $0.00
Total Liabilities $3.359M $3.305M $461.9K
YoY Change 511.74% 615.49% 36.02%
SHAREHOLDERS EQUITY
Retained Earnings -$55.23M -$54.50M -$50.38M
YoY Change 7.02% 8.17% 7.91%
Common Stock $49.39M $49.36M $48.74M
YoY Change 0.95% 1.27% 0.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.875M -$1.173M -$1.638M
YoY Change
Total Liabilities & Shareholders Equity $1.484M $2.132M $1.184M
YoY Change -19.03% 79.96% -42.54%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$678.5K -$632.7K -$881.9K
YoY Change -42.08% -28.26% 23.1%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$553.8K -$605.5K -$790.0K
YoY Change -42.08% -23.35% 6.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -99.18K 1.500M 10.00K
YoY Change -106.19% 14900.0% -80.0%
NET CHANGE
Cash From Operating Activities -553.8K -605.5K -790.0K
Cash From Investing Activities
Cash From Financing Activities -99.18K 1.500M 10.00K
Net Change In Cash -653.0K 894.5K -780.0K
YoY Change -200.97% -214.68% 13.04%
FREE CASH FLOW
Cash From Operating Activities -$553.8K -$605.5K -$790.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41296
CY2019Q2 us-gaap Assets Current
AssetsCurrent
2063207
CY2018Q4 us-gaap Assets Current
AssetsCurrent
1150009
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
195348
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
68346
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
82992
CY2019Q2 us-gaap Assets
Assets
2131553
CY2018Q4 us-gaap Assets
Assets
1233001
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2025200
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Liabilities
Liabilities
3304768
CY2018Q4 us-gaap Liabilities
Liabilities
1200650
CY2019Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
38007
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
384829
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49327674
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49015120
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
37045
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37008
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2131553
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1233001
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
304768
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
700650
CY2019Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10242
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
215876
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54498800
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52980643
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-1173215
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
303596
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
528875
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
331904
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
355531
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-635500
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-884406
CY2019Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2809
CY2018Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2490
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-632691
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-881916
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370446185
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369723717
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
500370
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1202845
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
926730
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
856377
CY2019Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
us-gaap Operating Income Loss
OperatingIncomeLoss
-1427100
us-gaap Operating Income Loss
OperatingIncomeLoss
-2059222
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8121
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6712
us-gaap Net Income Loss
NetIncomeLoss
-1418979
us-gaap Net Income Loss
NetIncomeLoss
-2052510
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370418176
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369669708
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
635500
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
884406
us-gaap Operating Expenses
OperatingExpenses
1427100
us-gaap Operating Expenses
OperatingExpenses
2059222
us-gaap Profit Loss
ProfitLoss
-1418979
us-gaap Profit Loss
ProfitLoss
-2052510
us-gaap Share Based Compensation
ShareBasedCompensation
212645
us-gaap Share Based Compensation
ShareBasedCompensation
292196
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17935
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-35243
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-395114
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-196151
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1583513
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1921222
hppi Proceeds From The Sale Of Preferred Stock And Common Stock Warrants Related Party Net
ProceedsFromTheSaleOfPreferredStockAndCommonStockWarrantsRelatedPartyNet
2360866
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
916487
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
451644
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
344113
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
795757
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
99178
CY2018Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
99945
CY2019Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
500000
CY2019Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49863
CY2019Q2 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-682554
CY2018Q2 hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-911834
CY2018Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
29918
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
99178
hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-1518157
hppi Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2109058
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
56548
hppi Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
2500000
us-gaap Stock Issued1
StockIssued1
99946
hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
99178
hppi Accrued But Unpaid Dividends
AccruedButUnpaidDividends
56548
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2372866
hppi Fair Value Inputs Royalty Rate
FairValueInputsRoyaltyRate
-0.70
CY2018Q4 us-gaap Deferred Revenue
DeferredRevenue
500000
CY2019Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1800000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-786288
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370084064
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-572275
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370084064
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
12000
hppi Description Of Royalty Payment
DescriptionOfRoyaltyPayment
With respect to each Advance made by Mayne Pharma prior to the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.75 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company, and with respect to each Advance made by Mayne Pharma following the receipt of FDA approval of an NDA for SUBA-Itraconazole BCCNS, each $0.85 increment of each such Advance will be credited and set off against each $1.00 increment of Royalty owed to the Company.
hppi Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size: 10pt; color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; margin-left: 0.79in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates</div></div></div><div style="font-size: 10pt; color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; margin-left: 0.79in;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</div></div><div style="font-size: 10pt; color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 18pt; margin-bottom: 0pt; margin-left: 0.79in; line-height: 12pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Revenue Recognition</div></div></div><div style="font-size: 10pt; color: rgb(0, 0, 0); font-family: &quot;times new roman&quot;; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; margin-top: 6pt; margin-bottom: 0pt; margin-left: 0.79in;">The Company currently has no ongoing source of revenues. Miscellaneous income, including interest, is recognized when earned by the Company. Deferred revenue represents cash received for royalties in advance of being earned. Such payments are reflected as deferred revenue until recognized under the Company&#8217;s revenue recognition policy. Deferred revenue would be classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue will be recognized when the product is sold and the related&#160;royalty is earned. Currently,&#160;all deferred revenue is related to the SUBA-Itraconazole BCCNS product, which is yet to be approved by FDA.&#160;As&#160;such,&#160;the Company has determined that 100% of the advances of the royalty received by Mayne Pharma should be classified as&#160;a&#160;<div style="white-space: nowrap; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">non-current&#160;liability.</div>&#160;At June&#160;30, 2019, deferred revenue consisted of $3.0&#160;million of royalties advanced by Mayne Pharma under the Third Amended SLA. There was $0.5&#160;million in deferred revenue at December&#160;31, 2018.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
26630
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
370446185
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2019Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
99946
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
131031
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1170594
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-822418
CY2018Q2 hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
12000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
83953
CY2018Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
29918
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-1638299
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
81614
CY2019Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
166563
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
208243
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false

Files In Submission

Name View Source Status
0001193125-19-219046-index-headers.html Edgar Link pending
0001193125-19-219046-index.html Edgar Link pending
0001193125-19-219046.txt Edgar Link pending
0001193125-19-219046-xbrl.zip Edgar Link pending
d747883d10q.htm Edgar Link pending
d747883dex311.htm Edgar Link pending
d747883dex312.htm Edgar Link pending
d747883dex321.htm Edgar Link pending
d747883dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20190630.xml Edgar Link completed
hppi-20190630.xsd Edgar Link pending
hppi-20190630_cal.xml Edgar Link unprocessable
hppi-20190630_def.xml Edgar Link unprocessable
hppi-20190630_lab.xml Edgar Link unprocessable
hppi-20190630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending